Lead modification: Amino acid appended indoles as highly effective 5-LOX inhibitors

Bioorganic and Medicinal Chemistry

Volumn 22, Issue 5, 2014, Pages 1642-1648

  Prasher, Parteek ^a   Pooja, ^a   Singh, Palwinder ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

5 LOX inhibition; Amino acid; Indole; Molecular modeling

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; GLUTAMIC ACID; GLYCINE; HISTIDINE; INDOLE DERIVATIVE; LEAD; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; N 1 TOSYL INDOLE DERIVATIVE; PROLINE; TRYPTOPHAN; UNCLASSIFIED DRUG; ZILEUTON; AMINO ACID;

AMINO ACID ANALYSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG IDENTIFICATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; CHEMICAL STRUCTURE;

AMINO ACIDS; INDOLES; LIPOXYGENASE INHIBITORS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84896694587     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2014.01.027     Document Type: Article

References (34)

1. W.H.O. data sheet 2012. www.who.int.
2. J. Sraer, M. Rigaud, M. Bens, H. Rabinovitch, and R. Ardaillou J. Biol. Chem. 258 1983 4325
3. P. Borgeat J. Med. Chem. 24 1981 121 and references therein
4. D.C. Zeldin J. Biol. Chem. 276 2001 31059 and references therein
5. Anna L. Blobaum, and Lawrence J. Marnette J. Med. Chem. 50 2007 1425
6. P. Singh, and A. Mittal Mini Rev. Med. Chem. 8 2008 73
7. J.Z. Haeggstrom, and C.D. Funk Chem. Rev. 111 2011 5866
8. M. Nakamura, and T. Shimizu Chem. Rev. 111 2011 6231
9. B. Samuelsson Angew. Chem., Int. Ed. Engl. 21 1982 902
10. G.A. Green Clin. Cornstone 3 2001 50
11. C. Pergola, and O. Werz Expert Opin. Ther. Pat. 20 2010 355
12. J.-M. Dogne, C.T. Supuran, and D. Pratico J. Med. Chem. 48 2005 2251
13. C. Leite-Pereira, C. Nunes, J.L.F.C. Lima, S. Reis, and M. Lucio J. Phys. Chem. 116 2012 13608
14. Food and Drug Administration, News release, September 30, 2004 and April 7, 2005.
15. P. Singh, and Pooja Bioorg. Med. Chem. Lett. 23 2013 1433 and references therein
16. A.H. Farghalay, and A. Rahman J. Chin. Chem. Soc. 51 2004 147
17. K. Benkli, S. Demirayak, G.N. Karaburun, N. Kiraz, G. Iscan, and U. Ucucu Ind. J. Chem. 43B 2004 174
18. D.M. Hiremath, S.C. Hiremath, and M.S. Yadawe Res. J. Pharm. Biol. Chem. Sci. 3 2012 969
19. T. Chandra, N. Garg, and A. Kumar Int. J. Chem. Tech. Res. 2 2010 762
20. V. Sharma, P. Kumar, and D. Pathak J. Heterocycl. Chem. 47 2010 491
21. M. Zheng, M. Zheng, D. Ye, Y. Deng, S. Qiu, X. Luo, K. Chen, H. Liu, and H. Jiang Bioorg. Med. Chem. Lett. 17 2007 2414
22. J. Landwehr, S. George, E.-M. Karg, D. Poeckel, D. Steinheilber, R. Troschuetz, and O. Werz J. Med. Chem. 49 2006 4327
23. A. Andreani, and M. Rambaldi J. Heterocycl. Chem. 25 1988 1519
24. 5-LOX inhibitor screening assay kit, Item No. 760700. Cayman Chemical Co.
25. G.W. Carter, P.R. Young, D.H. Albert, J. Bouska, R. Dyer, R.L. Bell, J.B. Summers, and D.W. Brooks J. Pharmacol. Exp. Ther. 256 1991 929
26. C. Brideau, C. Chan, S. Charleson, D. Denis, J.F. Evans, A.W. Ford-Hutchinson, R. Fortin, J.W. Gillard, J. Guay, and D. Guévremont et al. Can. J. Physiol. Pharmacol. 70 1992 799
27. www.molinspiration.com.
28. Cayman Chemical Co., Cat. No. 560131 (COX-1/2) and Cat no. 765021 (cPLA2).
29. W. Berger, M.T.M. De Chandt, and C.B. Cairns Int. J. Clin. Pract. 61 2007 663
30. For UV-visible spectral studies, same procedure was followed as reported for similar studies with DHFR. P. Singh, M. Kaur, and S. Sachdeva J. Med. Chem. 55 2012 6381
31. J.H. Hildebrand, and H.A. Benesi J. Am. Chem. Soc. 71 1949 2703
32. Y.C. Cheng, and W.H. Prusoff Biochem. Pharmcol. 22 1973 413
33. ArgusLab 4.0.1, M. A. Thompson, Planaria Software LLC, Seattle, WA 98155.
34. N.C. Gilbert, Z. Rui, D.B. Neau, M.T. Waight, S.G. Bartlett, W.E. Boeglin, A.R. Brash, and M.E. Newcomer FASEB J. 26 2012 3222